Cochrane · systematic review · CD010925
Interventions for fatigue in Parkinson's disease
Elbers, RG, Verhoef, J, van Wegen, EEH, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
Movement DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
44
current version
GRADE rated
44
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 4 · 9.1%Low 5 · 11.4%Moderate 32 · 72.7%High 3 · 6.8%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings levodopa‐carbidopa
Population: people with Parkinson's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Subjective impact of fatigue on ADL, fatigue severity (post‐intervention) | no estimate extracted | 1 study · 340 participants | Moderate Downgraded: imprecision |
Anxiety (adverse effect, post‐intervention) | RR 0.46 [0.15, 1.43] | 1 study · 361 participants | Moderate Downgraded: imprecision |
Headache (adverse effect,post‐intervention) | RR 2.66 [0.82, 8.61] | 1 study · 361 participants | Moderate Downgraded: imprecision |
Hypertension (adverse effect, post‐intervention) | RR 1 [0.28, 3.6] | 1 study · 361 participants | Moderate Downgraded: imprecision |
Nausea (adverse effect, post‐intervention) | RR 1.85 [1.05, 3.27] | 1 study · 361 participants | High |
Summary of findings memantine
Population: people with Parkinson's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Subjective impact of fatigue on ADL, fatigue severity (post‐intervention) | no estimate extracted | 1 study · 36 participants | Moderate Downgraded: imprecision |
Anxiety (adverse effect, post‐intervention) | RR 0.33 [0.01, 7.72] | 1 study · 40 participants | Moderate Downgraded: imprecision |
Hypertension (adverse effect, post‐intervention) | RR 0.33 [0.01, 7.72] | 1 study · 40 participants | Moderate Downgraded: imprecision |
Impulse control disorders (adverse effect, post‐intervention) | RR 3 [0.13, 69.52] | 1 study · 40 participants | Moderate Downgraded: imprecision |
Nausea (adverse effect, post‐intervention) | RR 0.14 [0.01, 2.6] | 1 study · 40 participants | Moderate Downgraded: imprecision |
HRQOL (post‐intervention) | no estimate extracted | 1 study · 36 participants | Moderate Downgraded: imprecision |
Summary of findings rasagiline
Population: people with Parkinson's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Subjective impact of physical fatigue on ADL (post‐intervention) | no estimate extracted | 1 study · 1176 participants | High |
Anxiety (adverse effect, post‐intervention) | RR 0.57 [0.33, 0.99] | 1 study · 1176 participants | High |
Headache (adverse effect, post‐intervention) | RR 0.8 [0.5, 1.29] | 1 study · 1176 participants | Moderate Downgraded: imprecision |
Hypertension (adverse effect, post‐intervention) | RR 0.53 [0.27, 1.06] | 1 study · 1176 participants | Moderate Downgraded: imprecision |
Impulse control disorders (adverse effect, post‐intervention) | RR 3.07 [0.13, 75.26] | 1 study · 1176 participants | Moderate Downgraded: imprecision |
Nausea (adverse effect, post‐intervention) | RR 0.89 [0.49, 1.6] | 1 study · 1176 participants | Moderate Downgraded: imprecision |
Orthostatic hypotension (adverse effect, post‐intervention) | RR 0.61 [0.15, 2.56] | 1 study · 1176 participants | Moderate Downgraded: imprecision |
Summary of findings caffeine
Population: people with Parkinson's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Subjective impact of fatigue on ADL, fatigue severity (post‐intervention) | no estimate extracted | 1 study · 61 participants | Moderate Downgraded: imprecision |
Subjective fatigue severity (post‐intervention) | no estimate extracted | 1 study · 61 participants | Moderate Downgraded: imprecision |
Anxiety (adverse effect, post‐intervention) | RR 1.03 [0.07, 15.78] | 1 study · 61 participants | Moderate Downgraded: imprecision |
Headache (adverse effect, post‐intervention) | RR 2.07 [0.2, 21.61] | 1 study · 61 participants | Moderate Downgraded: imprecision |
HRQOL (post‐intervention) | no estimate extracted | 1 study · 61 participants | Moderate Downgraded: imprecision |
Summary of findings methylphenidate
Population: people with Parkinson's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Subjective impact of fatigue on ADL, fatigue severity (post‐intervention) | no estimate extracted | 1 study · 34 participants | Moderate Downgraded: imprecision |
Subjective impact of physical fatigue on ADL (post‐intervention) | no estimate extracted | 1 study · 34 participants | Moderate Downgraded: imprecision |
Subjective impact of mental fatigue on ADL (post‐intervention) | no estimate extracted | 1 study · 34 participants | Moderate Downgraded: imprecision |
Headache (adverse effect, post‐intervention) | RR 0.24 [0.01, 4.62] | 1 study · 31 participants | Moderate Downgraded: imprecision |
Hypertension (adverse effect, post‐intervention) | RR 6 [0.31, 115.56] | 1 study · 31 participants | Moderate Downgraded: imprecision |
Nausea (adverse effect, post‐intervention) | RR 1.21 [0.08, 17.71] | 1 study · 31 participants | Moderate Downgraded: imprecision |
Tachycardia (adverse effect, post‐intervention) | RR 0.4 [0.02, 9.12] | 1 study · 31 participants | Moderate Downgraded: imprecision |
Summary of findings modafinil
Population: people with Parkinson's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Subjective impact of fatigue on ADL (post‐intervention) | no estimate extracted | 2 studies · 53 participants | Low Downgraded: risk of bias |
Subjective impact of physical fatigue on ADL (post‐intervention) | no estimate extracted | 1 study · 16 participants | Very low Downgraded: risk of bias |
Subjective impact of mental fatigue on ADL (post‐intervention) | no estimate extracted | 1 study · 16 participants | Low Downgraded: risk of bias |
Subjective fatigue severity (post‐intervention) | no estimate extracted | 1 study · 37 participants | Moderate Downgraded: risk of bias, imprecision |
Anxiety (adverse effect, post‐intervention) | RR 3.14 [0.35, 27.79] | 2 studies · 50 participants | Moderate Downgraded: risk of bias, imprecision |
Headache (adverse effect, post‐intervention) | RR 0.58 [0.07, 4.95] | 1 study · 13 participants | Moderate Downgraded: risk of bias, imprecision |
Hypertension (adverse effect, post‐intervention) | RR 3.43 [0.16, 71.36] | 1 study · 13 participants | Moderate Downgraded: risk of bias, imprecision |
Nausea (adverse effect, post‐intervention) | RR 1.01 [0.11, 8.93] | 2 studies · 50 participants | Moderate Downgraded: risk of bias, imprecision |
Summary of findings doxepin
Population: people with Parkinson's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Subjective impact of fatigue on ADL, fatigue severity (post‐intervention) | no estimate extracted | 1 study · 12 participants | Low Downgraded: risk of bias |
Nausea (adverse effect, post‐intervention) | RR 3 [0.15, 61.74] | 1 study · 12 participants | Very low Downgraded: risk of bias |
Orthostatic hypotension (adverse effect, post‐intervention) | RR 3 [0.15, 61.74] | 1 study · 12 participants | Very low Downgraded: risk of bias |
HRQOL (post‐intervention) | no estimate extracted | 1 study · 12 participants | Very low Downgraded: risk of bias |
Summary of findings exercise
Population: people with Parkinson's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Subjective impact of fatigue on ADL, fatigue severity (post‐intervention) | no estimate extracted | 2 studies · 57 participants | Low Downgraded: risk of bias |
HRQOL (post‐intervention) | no estimate extracted | 2 studies · 57 participants | Low Downgraded: risk of bias |